Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Context Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

About Context Therapeutics Inc.

Context Therapeutics Inc. is a biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors. Its pipeline includes candidates targeting CLDN6, MSLN, and Nectin-4, aiming to activate T cells against cancers with high unmet needs. The company leverages proprietary technologies, collaborates with partners, and relies on third-party manufacturing to develop targeted immunotherapies for global oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Context Therapeutics Inc.

1
1
Context Therapeutics Inc. Context Therapeutics Reports $8.7 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Context Therapeutics Inc. Context Therapeutics Reports $36.1 Million Net Loss and Increased Operating Expenses for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Context Therapeutics Inc. Context Therapeutics Reports $9.7 Million Net Loss in Q3 2025, Zero Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Context Therapeutics Inc. Context Therapeutics Reports $8.8 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Context Therapeutics Inc. Context Therapeutics Reports $4.6 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Context Therapeutics Inc. Context Therapeutics Reports $26.7 Million Net Loss and $29.9 Million Operating Expenses for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Context Therapeutics Inc. Context Therapeutics Reports Significant Financial Developments, Cash and Cash Equivalents Rise to $84.8 Million

Via official filing (AI summary) | over 1 year ago | 0 comments